Pharma Focus Europe

Siren Biotechnology and Catalent Announce Collaboration for Manufacturing AAV Gene Therapies Aimed at Cancer

Thursday, May 09, 2024

Siren Biotechnology, the pioneers behind Universal AAV Immuno-Gene Therapy for Cancer, have teamed up with Catalent Inc., a renowned provider of advanced treatments worldwide, in a strategic collaboration aimed at bolstering the development and production of Siren Biotechnology’s AAV immuno-gene therapies.

As part of this partnership, Catalent will be responsible for process development and cGMP manufacturing of Siren Biotechnology’s therapeutic candidates based on adeno-associated viral (AAV) vectors, intended for clinical trials. Additionally, Catalent will provide support towards process enhancement at its process and clinical development center located in Baltimore, MD.

Siren Biotechnology, expressed enthusiasm about collaborating with Catalent, highlighting their expertise in AAV vector development and manufacturing. She emphasized the significance of this partnership in advancing therapeutic programs swiftly into clinical phases. Dr. Paulk noted Catalent's distinction as the sole U.S.-based CDMO with FDA approval for AAV-based gene therapies, which significantly influenced the decision to collaborate, especially considering future plans for commercialization.

Catalent emphasized the company's commitment to early engagement with innovative partners like Siren. He expressed enthusiasm for pioneering the development and commercial production of safe, top-notch AAV gene therapies, with the ultimate goal of delivering life-saving treatments to cancer patients.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024